July 02, 2026 08:18 am (IST)
Follow us:
Detecting the onset of leprosy before nerve damage occurs
Birmingham, June 21 (IBNS) New research could help improve the lives of thousands of leprosy sufferers in India by detecting the disease long before it manifests as skin lesions. Peripheral nerve damage is the hallmark of leprosy pathology, but its origins had remained unclear until now.
Experts have been exploring the relationship between Mycobacterium leprae, a bacteria which causes leprosy, and the formation of the membrane attack complex (MAC), which is a tool deployed by the innate immune system to fight pathogens. MAC can damage adjacent health tissues and trigger inflammation at the early stages of the disease.
However, new research shows that inhibition of MAC formation reduces nerve damage and improves regeneration and functional recovery.
It is also suggested that biomarkers could be used to study the mechanism of autonomic neuropathy in general, with the aim of new drug development for autoimmune diseases such as diabetes, rheumatoid arthritis and lupus.
The research team consisted of Professor Pranab K. Das from the University of Birmingham and academics from the Institute of Lauro Souza Lima (ILSL) in Bauru, São Paulo, Brazil – where the research was carried out – along with the Academic Medical Center at the University of Amsterdam, Netherlands.
Professor Pranab K. Das, Honorary Senior Research Fellow, University of Birmingham said: "Our new research shows that inflammatory reactions can be prevented at an early stage of the disease, reducing the risk of the nerve damage that leads to the disabilities caused by leprosy. We propose that MAC inhibition could form the basis of the future development of novel therapeutics from leprosy."
Despite a marked decline in the number of cases of leprosy since the 1980s and effective multidrug therapy (MDT), the disease remains endemic in several countries, including India – where the disease is most prevalent. Almost 135,000 new cases of the disease were reported in India during 2012.
Professor Das warns that the fall in new case detection doesn’t mean that the disease is becoming less of a public health problem globally:
‘Our research has shown that fewer people have been diagnosed with leprosy in Brazil due to the decline in clinical knowledge about the disease, and we believe this may also be the case in India. Coupled with leprosy’s long incubation period, there also remains the stigma attached to those who have leprosy, which prevents many coming forward for treatment at the earliest stage.
‘The UK and Brazilian governments are now encouraging collaborative studies on neglected tropical diseases and I hope, going forward, we can initiate further research on leprosy, inflammation and nerve damage.’
However, new research shows that inhibition of MAC formation reduces nerve damage and improves regeneration and functional recovery.
It is also suggested that biomarkers could be used to study the mechanism of autonomic neuropathy in general, with the aim of new drug development for autoimmune diseases such as diabetes, rheumatoid arthritis and lupus.
The research team consisted of Professor Pranab K. Das from the University of Birmingham and academics from the Institute of Lauro Souza Lima (ILSL) in Bauru, São Paulo, Brazil – where the research was carried out – along with the Academic Medical Center at the University of Amsterdam, Netherlands.
Professor Pranab K. Das, Honorary Senior Research Fellow, University of Birmingham said: "Our new research shows that inflammatory reactions can be prevented at an early stage of the disease, reducing the risk of the nerve damage that leads to the disabilities caused by leprosy. We propose that MAC inhibition could form the basis of the future development of novel therapeutics from leprosy."
Despite a marked decline in the number of cases of leprosy since the 1980s and effective multidrug therapy (MDT), the disease remains endemic in several countries, including India – where the disease is most prevalent. Almost 135,000 new cases of the disease were reported in India during 2012.
Professor Das warns that the fall in new case detection doesn’t mean that the disease is becoming less of a public health problem globally:
‘Our research has shown that fewer people have been diagnosed with leprosy in Brazil due to the decline in clinical knowledge about the disease, and we believe this may also be the case in India. Coupled with leprosy’s long incubation period, there also remains the stigma attached to those who have leprosy, which prevents many coming forward for treatment at the earliest stage.
‘The UK and Brazilian governments are now encouraging collaborative studies on neglected tropical diseases and I hope, going forward, we can initiate further research on leprosy, inflammation and nerve damage.’
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Want to lose weight? Health expert shares her three simple rules
Wed, Jul 01 2026
Stop running flat! This cardio trick can help you burn more fat, says fitness expert
Mon, Jun 29 2026
“Endless scroll” warning: Shocking study reveals what short videos are doing to young brains
Sun, Jun 28 2026
Think summer sun is enough for Vitamin D? New study says think again
Sun, Jun 28 2026
Fitness enthusiast loses 25 kg by following just a few simple habits. What are they?
Sun, Jun 28 2026
Ebola reaches France: First confirmed case sparks health alert
Fri, Jun 26 2026
The secret to beating the dangers of sitting all day takes just 5 minutes, study reveals
Fri, Jun 26 2026
Scientists turn to cats for clues about healthy ageing — Here's why?
Wed, Jun 24 2026